Paxil (Top > Health > Drugs : Paxil) (6 Op Eds/11 General News/no Best Web OpEds/6 Life-Arts-Science/1 Diaries/no Polls/no Events)
Robert Fiddaman Dip.Couns MOC & MSFTR: Who Killed Japanese Culture? (1)
Lord Rudi C. Loehwing: *The 'Business' of Drugs: The Money behind Falsified Drug Research (4)
Salah Obeid: Pardoning Pittman (3)
Robert Fiddaman Dip.Couns MOC & MSFTR: Seroxat - The Main Culprits
Robert Fiddaman: A Chemical Imbalance - The Serotonin Myth (7)
Robert Fiddaman Dip.Couns MOC & MSFTR: MARKET THE DRUG... THEN MANUFACTURE THE DISEASE (3)
More OpEdNews_Op_Eds...
Nothing has been submitted for the category of Best_Web_OpEds
Martha Rosenberg: As Antidepressant Sales Sink Pharma Attacks FDA's Black Boxes (6)
Evelyn Pringle: The FDA Guerillas of Wonky DrugWonks - Part I
Evelyn Pringle: Glaxo Fights Against Public Paxil Trials (2)
Evelyn Pringle: Jury Trials In 2008 Expected To Expose SSRI Maker's Dirty Secrets
Martha Rosenberg: A Pill for Every Mood and Spokesman for Every Pill
Martha Rosenberg: The Many Faces of Big Pharma's Disease Mongering (1)
Martha Rosenberg: Like Merrill and Citi, Merck Wants to Forget a Lost Billion or Eight and Move On (1)
Evelyn Pringle: Women Not Warned About SSRI-Related Lung Birth Defect
Evelyn Pringle: Experts Say Birth Defect Risks Outweigh Benefits of SSRIs
More General_News...
Nothing has been submitted for the category of Events
Nothing has been submitted for the category of Polls
Robert Fiddaman Dip.Couns MOC & MSFTR: Paxil Study 329 All Over Again?
Robert Fiddaman Dip.Couns MOC & MSFTR: Glaxo, Myodil and The UK Regulator
Robert Fiddaman Dip.Couns MOC & MSFTR: MHRA and Fake Drugs
Robert Fiddaman Dip.Couns MOC & MSFTR: GlaxoSmithKline, David Healy & Shelley Joffre
Robert Fiddaman Dip.Couns MOC & MSFTR: MHRA 'No Comment'
Lynn Michaels: Keeping Children Safe: Alternatives to dangerous "off-label" [aka: unapproved] Antidepressant & Antipsychotic drugs
More Life_Arts_Science...
Robert Fiddaman Dip.Couns MOC & MSFTR: MHRA - Merely fanning the coals
More Diaries...
Copyright © 2002-2009, OpEdNews Powered by Populum